Results 311 to 320 of about 483,027 (406)

Targeting the Menin–KMT2A interaction in leukemia: Lessons learned and future directions

International Journal of Cancer, EarlyView.
Abstract Chromosomal rearrangements involving the Mixed Lineage Leukemia gene (MLL1, KMT2A) are defining a genetically distinct subset in about 10% of human acute leukemias. Translocations involving the KMT2A‐locus at chromosome 11q23 are resulting in the formation of a chimeric oncogene, where the N‐terminal part of KMT2A is fused to a variety of ...
Florian Perner, Jayant Y. Gadrey, Scott A. Armstrong, Michael W. M. Kühn   +3 more
wiley   +1 more source

miR-181a-5p mediates the effects of BMP4 on intestinal cell proliferation and differentiation. [PDF]

Cell Death Dis
Li C, Zhou Y, Yin Z, Jiang Y, Liu J, Weiss HL, Wang Q, Evers BM.   +7 more
europepmc   +1 more source

Therapeutic targeting of chromatin alterations in leukemia and solid tumors

International Journal of Cancer, EarlyView.
Abstract Alterations in chromatin conformation and post‐translational modification of histones have become increasingly recognized as critical drivers of cancer development, progression, and therapy resistance. Recent advances in drug development have led to the establishment of several highly selective small molecule inhibitors, several of which are ...
Florian Perner, Tobias Berg, Daniel Sasca, Sophie‐Luise Mersiowsky, Jayant Y. Gadrey, Johanna Thomas, Michael W. M. Kühn, Michael Lübbert   +7 more
wiley   +1 more source

The discovery of cyclin (I)

Cell, 2004
openaire   +2 more sources

Limited association between HRR gene alterations and HRD in molecular tumor board cancer samples: Who should be tested for HRD?

International Journal of Cancer, EarlyView.
What's New? Currently, no published data on homologous recombination deficiency (HRD) testing in the setting of molecular tumor boards exist. This study in a cohort of 237 patients encompassing 24 different tumor entities assessed by a molecular tumor board shows that inactivating alterations of BRCA1/2 are not always associated with an elevated ...
Christoph Schubart, Lars Tögel, Maria Giulia Carta, Philip Hetzner, Lina Helbig, Charlotte Zaglas, Maria Ziegler, Robert Stöhr, Annett Hölsken, Juliane Hoyer, Fulvia Ferrazzi, Clemens Neufert, Sebastian Lettmaier, Marianne Pavel, Henriette Golcher, Sarina K. Mueller, Florian Fuchs, Carla E. Schulmeyer, Matthias W. Beckmann, Bernd Wullich, Abbas Agaimy, Andre Reis, Arndt Hartmann, Norbert Meidenbauer, Silvia Spoerl, Florian Haller, Evgeny A. Moskalev   +26 more
wiley   +1 more source

SGO2 does not play an essential role in separase inhibition during meiosis I in mouse oocytes. [PDF]

PLoS Biol
Wetherall B, Bulmer D, Sarginson A, Thomas C, Madgwick S.   +4 more
europepmc   +1 more source

Mass cytometric detection of homologous recombination proficiency in circulating tumor cells to predict chemoresistance of metastatic breast cancer patients

International Journal of Cancer, EarlyView.
What's New? Circulating tumor cells can offer insights into treatment responses and metastatic recurrence, but current analysis methods are limited. Here, the authors tested a newly developed mass cytometry panel comprising biomarkers such as γH2AX and RAD51 in longitudinally monitored metastatic breast cancer patients.
Kathrin Niedermayer, Henning Schäffler, Georgios Vlachos, Sara Greco, Kerstin Pfister, Barbara Volz, Leonie Ott, Hans Neubauer, Bernhard Polzer, André Koch, Sabine Riethdorf, Tanja Fehm, Wolfgang Janni, Thomas W. P. Friedl, Brigitte Rack, Ellen Heitzer, Fabienne Schochter, Lisa Wiesmüller   +17 more
wiley   +1 more source

Safranal-loaded gold nanoparticles alleviate hepatocellular carcinoma via targeting the Wnt/β-catenin pathway. [PDF]

Discov Oncol
Samra YA, Abd El Salam ASG, Abdelghany AM, El-Shishtawy MM.   +3 more
europepmc   +1 more source